Cancer Letters
Volume 208, Issue 1 , Pages 115-122 , 10 May 2004

Integrin-linked kinase (ILK) regulation of the cell viability in PTEN mutant glioblastoma and in vitro inhibition by the specific COX-2 inhibitor NS-398

  • Soichi Obara

      Affiliations

    • Faculty of Medicine, Department of Neurosurgery, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan
    • Faculty of Medicine, Department of Laboratory and Molecular Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan
    • Corresponding Author InformationCorresponding author. Address: Faculty of Medicine, Department of Neurosurgery, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan. Tel.: +81-99-275-5437; fax: +81-99-275-2629
    • ,
  • Masanori Nakata

      Affiliations

    • Department of Physiology, Jichi Medical School, Minamikawachi, Kawachi, Tochigi 329-0498, Japan
    • ,
  • Hideo Takeshima

      Affiliations

    • Faculty of Medicine, Department of Neurosurgery, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan
    • ,
  • Hideki Katagiri

      Affiliations

    • Division of Molecular Metabolism and Diabetes, Department of Internal Medicine, Tohoku University Graduate School of Medicine Seiryo-machi, Sendai, 980-8574, Japan
    • ,
  • Tomoichiro Asano

      Affiliations

    • Faculty of Medicine, Department of Internal Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
    • ,
  • Yoshitomo Oka

      Affiliations

    • Division of Molecular Metabolism and Diabetes, Department of Internal Medicine, Tohoku University Graduate School of Medicine Seiryo-machi, Sendai, 980-8574, Japan
    • ,
  • Ikuro Maruyama

      Affiliations

    • Faculty of Medicine, Department of Laboratory and Molecular Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan
    • ,
  • Jun-ichi Kuratsu

      Affiliations

    • Faculty of Medicine, Department of Neurosurgery, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan

Received 10 November 2003 ,Revised 12 November 2003 ,Accepted 13 November 2003.

References 

  1. Kreth FW, Warnke PC, Scheremet R, Ostertag CB. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J. Neurosurg. 1993;78:762–766
  2. Kreth FW, Berlis A, Spiropoulou V, Faist M, Scheremet R, Rossner R, et al.  The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer. 1999;86:2117–2123
  3. Lyden DC, Mason WP, Finlay JL. The expanding role of chemotherapy for pediatric supratentorial malignant gliomas. J. Neurooncol. 1996;28:185–191
  4. Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, et al.  Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. 2000;1:195–203
  5. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 1997;57:2124–2129
  6. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–1947
  7. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 1997;15:356–362
  8. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, et al.  PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997;57:4187–4190
  9. Liu W, James CD, Frederick L, Alderete BE, Jenkins RB. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res. 1997;57:5254–5257
  10. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997;57:3660–3663
  11. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997;57:4997–5000
  12. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, et al.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997;57:5221–5225
  13. Kohno T, Takahashi M, Manda R, Yokota J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer. 1998;22:152–156
  14. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39
  15. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, et al.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl Acad. Sci. USA. 1999;96:6199–6204
  16. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl Acad. Sci. USA. 1999;96:2110–2115
  17. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231–241
  18. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al.  Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857–868
  19. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, et al.  Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature. 1996;379:91–96
  20. Attwell S, Roskelley C, Dedhar S. The integrin-linked kinase (ILK) suppresses anoikis. Oncogene. 2000;19:3811–3815
  21. Troussard AA, Costello P, Yoganathan TN, Kumagai S, Roskelley CD, Dedhar S. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene. 2000;19:5444–5452
  22. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl Acad. Sci. USA. 1998;95:11211–11216
  23. Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, et al.  Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J. Biol. Chem. 2001;276:27462–27469
  24. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc. Natl. Acad. Sci. USA. 2000;97:3207–3212
  25. Marotta A, Tan C, Gray V, Malik S, Gallinger S, Sanghera J, et al.  Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene. 2001;20:6250–6257
  26. Kuratsu J, Sato K, Saitoh Y, Takeshima H, Morioka M, Ushio Y. The mechanism of growth-regulation of glioma cells by trapidil. J. Neurooncol. 1995;23:201–206
  27. Ono H, Katagiri H, Funaki M, Anai M, Inukai K, Fukushima Y, et al.  Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes. Mol. Endocrinol. 2001;15:1411–1422
  28. Kitajima I, Kawahara K, Hanyu N, Shin H, Tokioka T, Soejima Y, et al.  Enhanced E-cadherin expression and increased calcium-dependent cell–cell adhesion in human T-cell leukemia virus type I Tax-expressing PC12 cells. J. Cell Sci. 1996;109(Pt3):609–617
  29. Li F, Zhang Y, Wu C. Integrin-linked kinase is localized to cell-matrix focal adhesions but not cell-cell adhesion sites and the focal adhesion localization of integrin-linked kinase is regulated by the PINCH-binding ANK repeats. J. Cell Sci. 1999;112(Pt 24):4589–4599
  30. Wang SC, Makino K, Xia W, Kim JS, Im SA, Peng H, et al.  DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. Oncogene. 2001;20:6960–6964
  31. Hannigan GE, Bayani J, Weksberg R, Beatty B, Pandita A, Dedhar S, et al. Mapping of the gene encoding the integrin-linked kinase, ILK, to human chromosome 11 p15.5–p15.4. Genomics. 1997;42:177–179
  32. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science. 1998;280:1614–1617
  33. Lin H, Bondy ML, Langford LA, Hess KR, Delclos GL, Wu X, et al.  Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin. Cancer Res. 1998;4:2447–2454
  34. Radeva G, Petrocelli T, Behrend E, Leung-Hagesteijn C, Filmus J, Slingerland J, et al. Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J. Biol. Chem. 1997;272:13937–13944
  35. White DE, Cardiff RD, Dedhar S, Muller WJ. Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene. 2001;20:7064–7072
  36. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001;61:4375–4381
  37. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK, et al.  Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 2000;60:4926–4931

PII: S0304-3835(03)00790-0

doi: 10.1016/j.canlet.2003.11.020

Cancer Letters
Volume 208, Issue 1 , Pages 115-122 , 10 May 2004

Article Tools

* Image Usage & Resolution